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and this was more evident in patients with arthroplasty. The
minimal score difference on 0–10 scale needed to detect clinical
improvement (worsening) was 0.64(0.75), 1.03(0.67), and
0.29(0.72) for pain, physical function, and stiffness domain,
respectively. CONCLUSIONS: WOMAC has good discrimina-
tive and evaluative properties. These properties provide an
opportunity to measure new health technologies and other inter-
ventions in this cohort of patients with conﬁdence. To beneﬁt
from the use of this measure as an interpretable one we 
need additional research in patients, particularly within 
clinical trials where other objective and interpretable measures
are used.
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ities (preferences) for 5 beneﬁt characteristics (route, physician
experience, onset, chance of beneﬁt, bone erosions), 6 common
adverse effects (injection site reaction, rash, oral ulcers, alopecia,
nausea, diarrhea), 4 rare adverse effects (cancer, nephrotoxicity,
hepatotoxicity, pneumonitis), and 1 cost characteristic (monthly
co-pay) were estimated using adaptive conjoint analysis. The 16
characteristics were based on four treatment choices: methotrex-
ate, gold, leﬂunomide, and etanercept. Based on the estimated
utilities for the 16 characteristics, the marginal rates of sub-
stitution between pairs of characteristics were computed.
RESULTS: Multiple BRC trade-off utilities were calculated and
will be presented. A subset of three of these BRC trade-off util-
ities is presented below. The utility lost by patients switching
from oral to subcutaneous injection was equal to the utility
gained from: incidence of rash decreasing from 40% to 9.5%;
nausea decreasing from 30% to 6.5%; diarrhea decreasing from
30% to 10.4%; or monthly co-pay lowered from $30 to $7.14.
For chance of beneﬁt versus onset trade-off, the range was from
-0.086 weeks/% (0.086 weeks of delay in the onset of the drug,
for a 1% increase in the chance of beneﬁt) to -0.244 weeks/%.
For onset versus diarrhea trade-off, the range was from 
-2.08%/week (2.08% reduction in the incidence of diarrhea, for
a one week delay in onset) to -7.23%/week. CONLCLUSIONS:
Patient preferences can be used to make explicit, the latent trade-
off decisions made by patients at the characteristics level in arriv-
ing at treatment choice decisions. This study methodology can
also be used to understand physician preferences for treatment
choices.
DIABETES—Clinical Outcomes Studies
PDB1
RETROSPECTIVE STUDY OF INSULIN GLARGINE USE IN
PREVIOUSLY INSULIN-NAIVE U.S. MANAGED CARE PATIENTS
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Wilmington, DE, USA
OBJECTIVES: Patient characteristics, treatment patterns, and
clinical effectiveness were assessed for insulin naïve patients with
type 2 diabetes (T2D) who initiated treatment with insulin
glargine. METHODS: Administrative and pharmacy claims were
linked with laboratory results from a large managed care data-
base and were analyzed between May 1, 2001 and May 31,
2004. Patients with a diagnosis of T2D who were insulin-naïve
prior to ﬁlling prescriptions for glargine were selected for analy-
sis and followed for a minimum of 12 months. The initial claim
for glargine served as the index date. Other antidiabetic therapy
was assessed for the month prior to the index date. Glargine
treatment patterns included persistence and concomitant med-
ications. A subset of patients receiving HbA1c results both
within 90 days pre- and no sooner than 60 days post-index
periods were analyzed for HbA1c changes. RESULTS: A total of
936 insulin-naïve patients with T2D who initiated glargine
therapy were identiﬁed. Prior to starting glargine, 50% of
patients received no antidiabetic therapy, 21% received oral
antidiabetic monotherapy, and 29% received combination oral
therapy. Post-index, 20% of patients received glargine alone,
while 80% received glargine in combination with short-acting
insulin (38%) and/or oral antidiabetic agents (42%). The
average length of glargine therapy was 185 days until a change
in the index therapy occurred. In patients with both pre-and
post-index values (N = 49), HbA1c decreased from 8.7% to
7.6% post-index (p = 0.0003). The average length of time
between index and post-index HbA1c measurement was 216
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BENEFIT-RISK-COST TRADE-OFF ANALYSES USING PATIENT
PREFERENCES FOR THE TREATMENT OF RHEUMATOID
ARTHRITIS
Arjunji RV, Dabbous OH, Rahman MI
Centocor, Inc, Horsham, PA, USA
OBJECTIVE: To estimate the beneﬁt-risk-cost (BRC) trade-off
at the patient level, utilizing patient preferences for treatment
choices in rheumatoid arthritis (RA). METHODS: Published
patient preferences on 120 RA patients with mean disease dura-
tion of 8 years was used to conduct these trade-off analyses. Util-
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days. Among patients with an HbA1c value post-index (N =
118), 28% reached the ADA target level of 7% or less. CON-
CLUSIONS: High pre-index HbA1c values may have con-
tributed to the relatively low proportion of T2D patients
achieving HbA1c goal after initiating glargine. This suggests an
opportunity for earlier and more aggressive pharmacotherapy
management of patients with T2D.
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GlucoWatch® Biographer G2TM (GWG2), in comparison to
standard self-monitoring of blood glucose. METHODS: Medline
MeSH heading searches of the published peer-reviewed clinical
literature identiﬁed all relevant studies since 2001. Technologies
were evaluated based on their ability to provide clinically accu-
rate glucose readings and improve glycemic control and overall
health outcomes. RESULTS: The available data surrounding
these devices is limited at this time because only GWG2 and GRT
are currently FDA approved. GWG2 demonstrated less than ade-
quate accuracy and a high false-positive rate (50–73%). DAY,
GRT and DEX demonstrated acceptable overall accuracy in
Clarke Error Grid studies (>95% zones A + B), however NAV is
the most accurate of the RTCGMs (99% overall, 92.4% during
hypoglycemia). Signiﬁcant data surrounding the effects of DAY,
DEX and NAV on glycemic control was not found, however
GWG2 was shown to have no positive, and perhaps a negative,
effect on glycemic control. Limited evidence with GRT revealed
a decrease in the frequency and duration of hypo- and hyper-
glycemic excursions. GWG2 which reported excessive skin irri-
tation in up to 76% of patients, often requiring discontinuation
of use, however the other RTCGMs displayed no signiﬁcant
adverse event occurrence. CONCLUSION: Given the limited evi-
dence presented in this assessment and based on its design and
preliminary clinical data, it appears that NAV is the most favor-
able of the RTCGMs. Fulﬁllment of customary health technol-
ogy assessment criteria will require FDA approval and additional
data documenting successful implementation.
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EARLY HEALTH TECHNOLOGY ASSESSMENT: CONTINUOUS
GLUCOSE MONITORING FOR THE MAINTENANCE OF
GLYCEMIC CONTROL IN INSULIN-REQUIRING TYPE 1
DIABETES
Marangos PJ1, Seybold P1, Papatheofanis FJ2
1Aequitas, San Diego, CA, USA, 2UCSD, San Diego, CA, USA
OBJECTIVE: Patient-interactive, real-time continuous glucose
monitors (RTCGMs) represent the future of diabetes manage-
ment and have the potential to improve health outcomes and
reduce diabetes-related complications. This assessment will eval-
uate the net health outcomes obtained in patients with insulin-
dependent diabetes while using RTCGMs such as the FreeStyle
NavigatorTM (NAV), GlucoDay® S (DAY), Guardian® RT
(GRT), DexComTM STSTM and Long-Term Systems (DEX) and
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